Softbank is pondering the sale or public listing of semiconductor firm ARM, its CEO has confirmed.
The Japanese conglomerate had planned to take ARM public in 2023 but, speaking on an earnings call, Masayoshi Son said the ownership structure could change sooner, with a number of options on the table.
"As one of the options that we may study or explore are the option of selling a part or some or full of the company," he said.
"Of course, another option is to bring forward the timing of IPO of this company. So that is another option that we can have. So we would like to closely study the best option."
Softbank acquired Cambridge-based ARM in 2016 for £24.3bn.
Son added that a relisting for the firm is "not that difficult", but said that any move would have to see Softbank make back its original investment.
Last month the investment firm said it planned to spin off two of ARM's IoT businesses, leaving it to solely focus on its semiconductor business.
Reports also suggested that Nvidia could be lined up as a potential suitor for ARM.
Dual-screen device runs Google's Android OS
We break down the key points on the rationale behind the move and how it will impact its MSP business
Move would establish MSP arm as a standalone company under existing president John Pagliuca
Tech company likely to shift operations to Vietnam facility
Nadella thanks Trump for his 'personal involvement'
Mike Norris has refused to pull his punches in interviews down the years. Here we round up 11 of his top zingers from the last decade...
New owner and executive chairman opens up on turbulent 2019 under previous owner and how he plans to breathe new life into the IT services company
Quarterly numbers reveal how each reseller fared during the peak of European COVID lockdowns
'Buyers hope to turn ashes into phoenixes' - How COVID-19 will shape MSP acquisitions in 2020 and 2021
Julian Box, founder and CEO of Calligo, an MSP that has completed seven acquisitions in the last three years, gives his take on how future M&A trends are being shaped by COVID-19